Top

Published in:

01-11-2008 | Research Article

BioEnterics Intragastric Balloon for Treatment of Morbid Obesity in Prader–Willi Syndrome: Specific Risks and Benefits

Authors: F. De Peppo, G. Di Giorgio, M. Germani, E. Ceriati, P. Marchetti, C. Galli, M. G. Ubertini, S. Spera, G. Ferrante, M. Cuttini, M. Cappa, G. Castelli Gattinara, M. Rivosecchi, A. Crinò

Published in: Obesity Surgery | Issue 11/2008

Abstract

Background

Obesity in Prader-Willi Syndrome (PWS) is progressive, severe, and resistant to dietary, pharmacological, and behavioral treatment. A body weight reduction is mandatory to reduce the risk of cardio-respiratory and metabolic complications. The aim of the study was to assess risks and benefits of BioEnterics Intragastric Balloon (BIB) for treatment of morbid obesity in PWS patients.

Methods

Twenty-one BIB were positioned in 12 PWS patients (4 M, 8 F), aged from 8.1 to 30.1 years, and removed after 8 ± 1.4 months (range: 5–10 months). Auxological, clinical, and nutritional evaluations were performed every 2 months. Variations in body composition were analysed by dual energy X-ray absorbiometry (DXA).

Results

One patient (28.5 years, BMI: 59.3 kg/m²) died 22 days after BIB positioning because of gastric perforation. In another case (26.2 years, BMI: 57.6 kg/m²), BIB was surgically removed after 25 days because of symptoms suggesting gastric perforation (not confirmed). The remaining ten patients showed a significant decrease of BMI (p = 0.005) and of fat tissue as measured by DXA (p = 0.012). No significant modifications in bone mineral density (BMD) occurred, but a slight loss in lean body mass (p = 0.036) was documented. In five patients, BIB treatment was repeated more than once.

Conclusion

This study shows that when noninvasive pharmacological therapies fail, BIB may be effective to control body weight in PWS patients with morbid obesity, particularly when treatment is started in early childhood. However, careful clinical follow-up and close collaboration with parents are crucial to avoid severe complications, which can be caused by persisting unrestrained food intake.

Goldstone AP. Prader–Willi syndrome: advances in genetics, pathophysiology and treatment. Trends Endocrinol Metab. 2004;15:12–20.PubMedCrossRef

Whittington JE, Holand AJ, Webb T, et al. Population prevalence and estimated birth incidence and mortality rate for people with Prader–Willi syndrome in one UK Health Region. J Med Genet. 2001;38:792–8.PubMedCrossRef

Burman P, Ritzen EM, Lindgren AC. Endocrine dysfunction in Prader–Willi syndrome: a review with special reference to GH. Endocr Rev. 2001;22(6):787–99.PubMedCrossRef

Butler MG. Management of obesity in Prader–Willi syndrome. Nat Clin Pract Endocrinol Metab. 2006;2:592–3.PubMedCrossRef

Nieben OG, Harboe H. Intragastric balloon as an artificial bezoar for treatment of obesity. Lancet. 1982;1:198–9.PubMed

Doldi SB, Micheletto G, Perrini MN, et al. Intragastric balloon: another option for treatment of obesity and morbid obesity. Hepatogastroenterology. 2004;51:294–7.PubMed

Roman S, Napoleon B, Mion F, et al. Intragastric balloon for “non-morbid” obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14:539–44.PubMedCrossRef

Genco A, Bruni T, Doldi SB, et al. Bioenterics intragastric balloon: the Italian experience with 2515 patients. Obes Surg. 2005;15:1161–4.PubMedCrossRef

Herve J, Wahlen H, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70.PubMedCrossRef

10.

Galloro G, De Palma GD, Catanzano C, et al. Preliminary endoscopic technical report of a new silicone intragastric balloon in the treatment of morbid obesity. Obes Surg. 1999;9:68–71.PubMedCrossRef

11.

Tottè E, Hendrickx L, Pauwels M, et al. Weight reduction by means of intragastric device: experience with the bioenterics intragastric balloon. Obes Surg. 2001;11:519–23.PubMedCrossRef

12.

Holm VA, Cassidy SB, Butler MG, et al. Prader–Willi syndrome: consensus diagnostic criteria. Pediatrics. 1993;91:398–402.PubMed

13.

Fonkalsrud EW, Bray G. Vagotomy for treatment of obesity in childhood due to Prader–Willi syndrome. J Pediatr Surg. 1981;16:888–9.PubMedCrossRef

14.

Touquet VL, Ward MW, Clark CG. Obesity surgery in a patient with Prader–Willi syndrome. Br J Surg. 1983;70:180–6.PubMedCrossRef

15.

Smith R, Kouvalainen K. Jejunoileal bypass for morbidly obese adolescence. Acta Paediatr Scand. 1975;Suppl:62–3.

16.

Dousei T, Miyata M, Izukura M, et al. Long term follow up of gastroplasty in a patient with Prader–Willi syndrome. Obes Surg. 1992;2:189–93.PubMedCrossRef

17.

Mason EE, Scott DH, Doherty C, et al. Vertical banded gastroplasty in the severely obese under age twenty-one. Obes Surg. 1995;5:23–33.PubMedCrossRef

18.

Chelala E, Cadiere GB, Favretti F, et al. Conversion and complication in 185 laparoscopic adjustable silicone gastric banding cases. Surg Endosc. 1997;11:268–71.PubMedCrossRef

19.

Kobayashi J, Kodama M, Yamazaki K, et al. Gastric bypass in a Japanese man with Prader–Willi syndrome and morbid obesity. Obes Surg. 2003;13(5):803–5.PubMedCrossRef

20.

Laurent-Jaccard A, Hofstetter JR, Saegesser F, et al. Long-term result of treatment of Prader–Willi syndrome by Scopinaro’s biliopancreatic diversion. Study of three cases and the effect of dextrofenfluramine on the postoperative evolution. Obes Surg. 1991;1:83–7.PubMedCrossRef

21.

Marinari GM, Camerini G, Novelli GB, et al. Outcome of biliopancreatic diversion in subjects with Prader–Willi syndrome. Obes Surg. 2001;11(4):491–5.PubMedCrossRef

22.

Grugni G, Guzzaloni G, Morabito F. Failure of biliopancreatic diversion in Prader–Willi syndrome. Obes Surg. 2000;10:179–81.PubMedCrossRef

23.

Antal S, Levin H. Biliopancreatic diversion in Prader–Willi syndrome associated with obesity. Obes Surg. 1996;6:58–62.PubMedCrossRef

24.

de Aldeide MQ, Cercato C, et al. Results of biliopancreatic diversion in two patients with Prader–Willi syndrome. Obes Surg. 2005;15(6):901–4.CrossRef

25.

Papavramidis ST, Kotidis EV, Gamvros O. Prader–Willi syndrome-associated obesity treated by biliopancreatic diversion with duodenal switch. Case report and literature review. J Pediatr Surgery. 2006;41:1153–8.CrossRef

26.

Papadia FS, Adami GF, Marinari GM, et al. Bariatric surgery in adolescents: a long-term follow-up study. Surg Obes Relat Dis. 2007;30:465–8, Mar 30.CrossRef

27.

Grugni G, Crinò A, Bosio L, et al. The Italian national survey for Prader–Willi syndrome: an epidemiologic study. Am J Med Genet A. 2008;146A:861–72, Jan 17.CrossRef

Title: BioEnterics Intragastric Balloon for Treatment of Morbid Obesity in Prader–Willi Syndrome: Specific Risks and Benefits
Authors: F. De Peppo
G. Di Giorgio
M. Germani
E. Ceriati
P. Marchetti
C. Galli
M. G. Ubertini
S. Spera
G. Ferrante
M. Cuttini
M. Cappa
G. Castelli Gattinara
M. Rivosecchi
A. Crinò
Publication date: 01-11-2008
Publisher: Springer-Verlag
Published in: Obesity Surgery / Issue 11/2008
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-008-9509-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

BioEnterics Intragastric Balloon for Treatment of Morbid Obesity in Prader–Willi Syndrome: Specific Risks and Benefits

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2008

Impact of Morbid Obesity on Chewing Ability

Vomiting and An Abdominal Mass Immediately After Vaginal Delivery: An Unusual Cause

Inadequate Weight Loss vs Secondary Weight Regain: Laparoscopic Conversion from Gastric Banding to Roux-en-Y Gastric Bypass

Band and Port-Related Morbidity After Bariatric Surgery: An Underestimated Problem

Therapeutic Effects of Sleeve Gastrectomy Plus Gastric Remnant Banding on Weight Reduction and Gastric Dilatation: An Animal Study

The Eradication of Helicobacter pylori is Affected by Body Mass Index (BMI)